Etirinotecan Pegol (NKTR-102) in Patients With Active Brain Metastases From Lung or Breast Cancer.
Saved in:
| Title: | Etirinotecan Pegol (NKTR-102) in Patients With Active Brain Metastases From Lung or Breast Cancer. |
|---|---|
| Authors: | Nagpal S; Department of Neurology, Division of Neuro-Oncology, Stanford University, Stanford, California, USA., Nguyen KS; Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA., Bertrand S; Department of Neurology, Division of Neuro-Oncology, Stanford University, Stanford, California, USA., Cunanan KM; Quantitative Sciences Unit, School of Medicine, Stanford University, Stanford, California, USA., Padda SK; Fox Chase Cancer Center, Temple University, Philadelphia, Pennsylvania, USA., Pagtama JY; Stanford Health Care, Stanford, California, USA., Tisch AH; Stanford Health Care, Stanford, California, USA., Coffey G; Stanford Health Care, Stanford, California, USA., Thomas RP; Department of Neurology, Division of Neuro-Oncology, Stanford University, Stanford, California, USA., Sledge GW Jr; Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA., Gruber J; UT Southwestern Medical Center, Dallas, Texas, USA., Telli ML; Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA., Pegram M; Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA., Recht LD; Department of Neurology, Division of Neuro-Oncology, Stanford University, Stanford, California, USA., Wakelee HA; Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA., Soltys SG; Department of Radiation Oncology, Stanford University, Stanford, California, USA., Massarweh SA; Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA., Neal JW; Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA. |
| Source: | Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2025 Sep; Vol. 8 (9), pp. e70330. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101747728 Publication Model: Print Cited Medium: Internet ISSN: 2573-8348 (Electronic) Linking ISSN: 25738348 NLM ISO Abbreviation: Cancer Rep (Hoboken) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2573-8348 |
|---|---|
| DOI: | 10.1002/cnr2.70330 |
